Veirulence

1 known investors

Veirulence develops first-in-class non-antibiotic small molecule therapeutics that target bacterial virulence factors to treat resistant infections, with an initial focus on the WHO priority pathogen Pseudomonas aeruginosa. The company aims to address antimicrobial resistance in hospital-acquired bacterial infections.

BiotechDeep TechHealthtech